Lead Optimization: From Promising Lead to Development-Ready Candidate
Refine your lead compounds into Pre-Clinical Candidates with the potency, selectivity, and drug-like properties to succeed in development through multi-parameter optimization, integrated CADD, and advanced synthesis technologies, all coordinated within a single expert team.
01 — SERVICE DESCRIPTION
Lead Optimization Strategy
Lead Optimization is where scientific rigor meets strategic foresight. This complex, multi-parameter process refines a promising lead into a Pre-Clinical Candidate (PCC), simultaneously addressing potency, selectivity, ADMET, mutagenicity, synthetic accessibility, and IP position. The stakes are high: a poorly optimized lead can derail an entire drug discovery program. At Oxeltis, we transform this challenge into a strategic advantage, combining medicinal chemistry expertise, cutting-edge synthesis technologies, and data-driven insights to deliver development-ready candidates efficiently.
- Our approach aligns custom synthesis with biological, DMPK, and early safety feedback in a tight iterative loop.
In collaboration with Molecular Forecaster, in silico design predicts and mitigates liabilities before compounds are made, while our SFC purification platform enables rapid, high-purity scale-up of up to 25 grams per day, even for complex or chiral structures. Early mutagenicity screening via GenEvolutioN (NANOAMES, ICH M7 alerts) surfaces genotoxic liabilities early, when they can still be engineered out rather than discovered in IND-enabling toxicology.
A dedicated project leader coordinates every workstream, ensuring that each design cycle moves the client's program measurably closer to candidate nomination.
Key deliverables
02 — PROCESS / HOW IT WORKS
How our Lead Optimization service works
01
Lead Profiling & Priority Setting
We assess the client's lead series, potency, selectivity, ADMET flags, IP status, and synthetic route, and define the multi-parameter optimization strategy for the campaign.
02
In Silico Design & Liability Mitigation
Computational modeling via Molecular Forecaster (docking, FEP, metabolic prediction, and GenAI-driven ideation) identifies liabilities and prioritizes structural modifications before synthesis, saving time and resources.
03
Precision Synthesis & Scale-Up
Targeted analogs synthesized using the most appropriate methodology for each scaffold, with scalability built into the route from the outset for seamless progression to IND-enabling quantities.
04
Integrated DMPK & PCC Selection
ADMET and pharmacokinetic data and early mutagenicity flags (via GenEvolutioN) feed directly back into the next design cycle until a Pre-Clinical Candidate meeting all target criteria is nominated.
03 — USE CASES / APPLICATIONS
Where Lead Optimization makes the biggest difference
04 — WHY OXELTIS
Why choose Oxeltis for Lead Optimization
- Multi-parameter optimization — potency, ADMET, IP, and scalability in a single program
A program needs to expand its IP estate while advancing toward a development candidate. Novel chemical space exploration, computationally guided and synthetically validated, secures patentable analogs alongside the PCC nomination package.
- In silico design integrated at every cycle — not bolted on
In collaboration with Molecular Forecaster, computational predictions, binding affinity, metabolic stability, selectivity, ADMET, are generated before each synthesis batch. Every analog synthesized is justified by data, and liabilities are identified and addressed before they become program-stopping issues.
- Early safety triage inside the loop, not after it
Mutagenicity screening via GenEvolutioN (NANOAMES, ICH M7) runs within the design cycle rather than as a late gate, so genotoxic structural alerts are engineered out during optimization instead of surfacing as costly surprises in IND-enabling toxicology.
- Advanced synthesis technologies for the most demanding structural modifications
Flow chemistry, photochemistry, mechanochemistry, and SPPS are deployed where standard batch protocols are insufficient, giving access to the structural space needed to solve selectivity and metabolic stability challenges that cannot be addressed through incremental SAR.
- Scalability by design — from optimization to IND-enabling quantities
We engineer synthetic routes for scalability from day one. The routes used during optimization are the same ones that carry the PCC through ADME, toxicology, and IND-enabling studies, without costly route redesign as quantities scale up to 25 g/day and beyond.
Ready to advance your lead toward a Pre-Clinical Candidate?
Tell us about your lead series and optimization objectives — we'll come back to you within 48 hours with a tailored proposal.
« * » indique les champs nécessaires